On Wednesday, Alcoa Inc (NYSE:AA)’s shares declined -3.23% to $8.08.
AA has 62.00% institutional ownership while its EPS ratio was 0.39. The company has 1.31 billion shares outstanding while market capitalization of the company was $10.94 billion. Price to book ratio was 0.83. Net profit margin of the company was 2.00% while gross profit margin was 21.20%. Stock volatility for the month was booked as 3.81% while for the week was recorded as 3.43%.
The mean estimate for the short term price target for Alcoa Inc (NYSE:AA) stands at $11.85 according to 13 Analysts. The higher price target estimate for the stock has been calculated at $15.00 while the lower price target estimate is at $8.00.
Analysts mean recommendation for the stock is 2.30. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Alcoa Inc. (Alcoa) is engaged in lightweight metals engineering and manufacturing. The Company operates in four segments: Alumina, Primary Metals, Global Rolled Products, and Engineered Products and Solutions.
Anavex Life Sciences Corp (OTCMKTS:AVXL)’s shares showed no change to $5.44.
AVXL has the market capitalization of $170.30 million. The stock has P/B ratio of -15.54 while EPS was $-1.19. Institutional ownership of the company was 6.40% while 30.11 million shares were outstanding. Share of the company moved below its SMA 50 with -46.23%. ROE ratio was -546.70% .
The mean estimate for the short term price target for Anavex Life Sciences Corp (OTCMKTS:AVXL) stands at $10.16 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $15.00 while the lower price target estimate is at $5.32.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.
At the end of Wednesday’s trade, Clean Energy Fuels Corp (NASDAQ:CLNE)‘s shares dipped -8.47% to $5.08.
CLNE has market capitalization of $502.68 million. Its current ratio was 1.30 while its shares were below its 50 days simple moving average with -2.40%. The company offered earning per share of $-0.91 while its 90.57 million shares were outstanding. YTD performance of the company was 1.7%. Stock volatility for the week was 7.96% while for the month it was shown at 8.11%.
The mean estimate for the short term price target for Clean Energy Fuels Corp (NASDAQ:CLNE) stands at $7.80 according to 5 Analysts. The higher price target estimate for the stock has been calculated at $15.00 while the lower price target estimate is at $3.00.
Analysts mean recommendation for the stock is 3.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Clean Energy Fuels Corp. is a provider of natural gas as an alternative fuel for vehicle fleets in the United States and Canada. The Company designs, builds, operates and maintains fueling stations and supplies its customers with compressed natural gas (CNG) fuel for light, medium and heavy-duty vehicles and liquefied natural gas (LNG) fuel for medium and heavy-duty vehicles.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.